Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Home Page: www.alnylam.com
ALNY Technical Analysis
675 West Kendall Street
Cambridge,
MA
02142
United States
Phone:
617 551 8200
Officers
| Name | Title |
|---|---|
| Mr. Michael W. Bonney B.A. | Exec. Chairman |
| Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB | CEO & Director |
| Dr. Akshay K. Vaishnaw M.D., Ph.D. | Pres |
| Mr. Jeffrey V. Poulton M.B.A. | CFO & Exec. VP |
| Mr. Tolga Tanguler M.B.A. | Exec. VP & Chief Commercial Officer |
| Dr. Alfred W. Boyle Ph.D. | Chief Technical Operations & Quality Officer |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Sr. VP, Head of Research & Chief Scientific Officer |
| Ms. Christine Regan Lindenboom | Sr. VP of Investor Relations & Corp. Communications |
| Ms. Indrani M. Lall Franchini J.D. | Exec. VP, Chief Legal Officer & Sec. |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 142.9249 |
| Price-to-Sales TTM: | 29.3666 |
| IPO Date: | 2004-05-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 1665 |